Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2015
At a glance
- Drugs BI 2536 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 03 Jul 2012 Planned number of patients changed from 185 to 220 as reported by European Clinical Trials Database record.
- 08 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
- 04 Oct 2006 New trial record.